Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19 : A meta-analysis of individual participant data of randomized trials
© 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics..
Hydroxychloroquine (HCQ) was initially promoted as an oral therapy for early treatment of coronavirus disease 2019 (COVID-19). Conventional meta-analyses cannot fully address the heterogeneity of different designs and outcomes of randomized controlled trials (RCTs) assessing the efficacy of HCQ in outpatients with mild COVID-19. We conducted a pooled analysis of individual participant data from RCTs that evaluated the effect of HCQ on hospitalization and viral load reduction in outpatients with confirmed COVID-19. We evaluated the overall treatment group effect by log-likelihood ratio test (-2LL) from a generalized linear mixed model to accommodate correlated longitudinal binary data. The analysis included data from 11 RCTs. The outcome of virological effect, assessed in 1560 participants (N = 795 HCQ, N = 765 control), did not differ significantly between the two treatment groups (-2LL = 7.66; p = 0.18) when adjusting for cohort, duration of symptoms, and comorbidities. The decline in polymerase chain reaction positive tests from day 1 to 7 was 42.0 and 41.6 percentage points in the HCQ and control groups, respectively. Among the 2037 participants evaluable for hospitalization (N = 1058 HCQ, N = 979 control), we found no significant differences in hospitalization rate between participants receiving HCQ and controls (odds ratio 0.995; 95% confidence interval 0.614-1.610; -2LL = 0.0; p = 0.98) when adjusting for cohort, duration of symptoms, and comorbidities. This individual participant data meta-analysis of 11 HCQ trials that evaluated severe acute respiratory syndrome-coronavirus 2 viral clearance and COVID-19 hospitalization did not show a clinical benefit of HCQ. Our meta-analysis provides evidence to support the interruption in the use of HCQ in mild COVID-19 outpatients to reduce progression to severe disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Clinical and translational science - 16(2023), 3 vom: 18. März, Seite 524-535 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mitjà, Oriol [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 27.03.2023 Date Revised 14.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cts.13468 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351128557 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351128557 | ||
| 003 | DE-627 | ||
| 005 | 20231226050612.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cts.13468 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1170.xml |
| 035 | |a (DE-627)NLM351128557 | ||
| 035 | |a (NLM)36601684 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mitjà, Oriol |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19 |b A meta-analysis of individual participant data of randomized trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.03.2023 | ||
| 500 | |a Date Revised 14.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. | ||
| 520 | |a Hydroxychloroquine (HCQ) was initially promoted as an oral therapy for early treatment of coronavirus disease 2019 (COVID-19). Conventional meta-analyses cannot fully address the heterogeneity of different designs and outcomes of randomized controlled trials (RCTs) assessing the efficacy of HCQ in outpatients with mild COVID-19. We conducted a pooled analysis of individual participant data from RCTs that evaluated the effect of HCQ on hospitalization and viral load reduction in outpatients with confirmed COVID-19. We evaluated the overall treatment group effect by log-likelihood ratio test (-2LL) from a generalized linear mixed model to accommodate correlated longitudinal binary data. The analysis included data from 11 RCTs. The outcome of virological effect, assessed in 1560 participants (N = 795 HCQ, N = 765 control), did not differ significantly between the two treatment groups (-2LL = 7.66; p = 0.18) when adjusting for cohort, duration of symptoms, and comorbidities. The decline in polymerase chain reaction positive tests from day 1 to 7 was 42.0 and 41.6 percentage points in the HCQ and control groups, respectively. Among the 2037 participants evaluable for hospitalization (N = 1058 HCQ, N = 979 control), we found no significant differences in hospitalization rate between participants receiving HCQ and controls (odds ratio 0.995; 95% confidence interval 0.614-1.610; -2LL = 0.0; p = 0.98) when adjusting for cohort, duration of symptoms, and comorbidities. This individual participant data meta-analysis of 11 HCQ trials that evaluated severe acute respiratory syndrome-coronavirus 2 viral clearance and COVID-19 hospitalization did not show a clinical benefit of HCQ. Our meta-analysis provides evidence to support the interruption in the use of HCQ in mild COVID-19 outpatients to reduce progression to severe disease | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 700 | 1 | |a Reis, Gilmar |e verfasserin |4 aut | |
| 700 | 1 | |a Boulware, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Spivak, Adam M |e verfasserin |4 aut | |
| 700 | 1 | |a Sarwar, Ammar |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Webb, Brandon |e verfasserin |4 aut | |
| 700 | 1 | |a Hill, Michael D |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Davey |e verfasserin |4 aut | |
| 700 | 1 | |a Kremsner, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Curran, Marla |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, David |e verfasserin |4 aut | |
| 700 | 1 | |a Alexander, Jim |e verfasserin |4 aut | |
| 700 | 1 | |a Corbacho, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Todd C |e verfasserin |4 aut | |
| 700 | 1 | |a Hullsiek, Katherine Huppler |e verfasserin |4 aut | |
| 700 | 1 | |a McDonald, Emily G |e verfasserin |4 aut | |
| 700 | 1 | |a Hess, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Baeten, Jared M |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartz, Ilan |e verfasserin |4 aut | |
| 700 | 1 | |a Metz, Luanne |e verfasserin |4 aut | |
| 700 | 1 | |a Richer, Lawrence |e verfasserin |4 aut | |
| 700 | 1 | |a Chew, Kara W |e verfasserin |4 aut | |
| 700 | 1 | |a Daar, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Wohl, David |e verfasserin |4 aut | |
| 700 | 1 | |a Dunne, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational science |d 2008 |g 16(2023), 3 vom: 18. März, Seite 524-535 |w (DE-627)NLM186388268 |x 1752-8062 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:3 |g day:18 |g month:03 |g pages:524-535 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cts.13468 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 3 |b 18 |c 03 |h 524-535 | ||